Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129137 | 0.88 | MAOB (0.58) | MAOBMRGPRX4GAAMAPTMAOA | |
| SCHEMBL18034568 | 0.87 | MAOB (0.48) | MAOBMRGPRX4GAAMAPTMAOA | |
| SCHEMBL17629916 | 0.83 | CYP11B1 (0.50) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1330628 | 0.83 | MAOB (0.62) | MAOBMRGPRX4XDH | |
| SCHEMBL70797 | 0.83 | MAOB (0.60) | MAOBMRGPRX4MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6477064 | 0.82 | MAOB (0.55) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20302267 | 0.81 | MAOB (0.58) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6072398 | 0.81 | MAOB (0.58) | MAOBMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6061295 | 0.81 | MAOB (0.58) | MAOBMRGPRX4RAB9ASMN1; SMN2CYP19A1 | |
| SCHEMBL5241760 | 0.81 | MAOB (0.50) | MAOBMRGPRX4GAAMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | UNIVERZA V LJUBLJANI (SI) | 2025-03-25 | — | — | US | disclosed |
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | UNIVERZA V LJUBLJANI (SI) | 2021-10-21 | — | — | US | disclosed |
| EP-3847172-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | Univerza v Ljubljani (SI) | 2021-07-14 | — | — | EP | disclosed |
| CN-1252054-C | Qinoline derivatives inhibiting effect of growth factors such as VEGF | ZENECA LTD (GB) | 2006-04-19 | — | — | CN | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOP1, TOP2A, TOP2B | MAOB 1631/4885MRGPRX4 3070/4885GAA 72/4885 |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | TOP1, TOP2A, TOP2B | MAOB 1415/4885MRGPRX4 3558/4885GAA 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.